TY - JOUR
T1 - International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
AU - Wingerchuk, Dean M.
AU - Banwell, Brenda
AU - Bennett, Jeffrey L.
AU - Cabre, Philippe
AU - Carroll, William
AU - Chitnis, Tanuja
AU - De Seze, Jérôme
AU - Fujihara, Kazuo
AU - Greenberg, Benjamin
AU - Jacob, Anu
AU - Jarius, Sven
AU - Lana-Peixoto, Marco
AU - Levy, Michael
AU - Simon, Jack H.
AU - Tenembaum, Silvia
AU - Traboulsee, Anthony L.
AU - Waters, Patrick
AU - Wellik, Kay E.
AU - Weinshenker, Brian G.
N1 - Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
AB - Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
UR - http://www.scopus.com/inward/record.url?scp=84940730364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940730364&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000001729
DO - 10.1212/WNL.0000000000001729
M3 - Review article
C2 - 26092914
AN - SCOPUS:84940730364
SN - 0028-3878
VL - 85
SP - 177
EP - 189
JO - Neurology
JF - Neurology
IS - 2
ER -